Both hit GLP-1 and GIP receptors. Only retatrutide adds glucagon. That one difference produces ~3% more weight loss — and a completely different energy expenditure profile.
Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist — FDA approved, Phase 3 data showing ~20–22% weight loss, and a rapidly growing clinical evidence base. Retatrutide adds glucagon receptor agonism to that same GLP-1/GIP foundation, producing ~24% weight loss in Phase 2 — but with no FDA approval yet and less long-term safety data. Tirzepatide is the validated option; retatrutide is the next step up that's still in Phase 3.
Tirzepatide and retatrutide share the same GLP-1 and GIP receptor activation. The only pharmacological difference is retatrutide's additional glucagon receptor (GcgR) agonism. Understanding what that adds explains why retatrutide shows greater weight loss despite the overlap.
Both compounds reduce appetite via GLP-1's central and peripheral effects, improve insulin secretion via GIP's incretin effects, slow gastric emptying, and reduce post-meal glucose spikes. This shared foundation is why both produce substantial weight loss and glycemic improvement.
Glucagon receptor activation increases hepatic glucose production in isolation — but in the context of simultaneous GLP-1 and GIP activity, the insulin-raising effects counterbalance the hyperglycemic risk. What remains are glucagon's metabolic effects that GLP-1/GIP don't produce: increased thermogenesis (brown adipose tissue activation), enhanced hepatic fat oxidation, and direct lipolytic effects on white adipose tissue. These mechanisms explain the additional ~2–3% weight loss retatrutide produces over tirzepatide in Phase 2 comparisons.
The gap between tirzepatide and retatrutide (~21% vs ~24%) is smaller than the gap between semaglutide and tirzepatide (~15% vs ~21%). Adding the third receptor produces diminishing returns compared to the first addition. But at this level of weight loss, even 2–3% additional reduction represents meaningful clinical difference — particularly for patients who don't respond adequately to dual agonism.
| Factor | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GLP-1R, GIPR | GLP-1R, GIPR, GcgR |
| Weight loss (clinical) | ~20.9% (SURMOUNT-1, 72 weeks) | ~24.2% (Phase 2, 48 weeks) |
| FDA approval | Yes (Zepbound 2023, Mounjaro 2022) | No — Phase 3 ongoing |
| Dosing | Once weekly SubQ (2.5–15mg) | Once weekly SubQ (1–12mg) |
| Half-life | ~5 days | ~6 days |
| Energy expenditure | Modest (GIP contribution) | Greater (glucagon thermogenesis) |
| Liver fat reduction | Significant (NASH trial data) | Greater in Phase 2 (GLP-1+GCG) |
| Manufacturer | Eli Lilly (Mounjaro/Zepbound) | Eli Lilly |
| Phase 3 status | Completed — approved | Ongoing |
| Long-term safety data | Growing post-market dataset | Limited to Phase 2 |
The SURMOUNT-1 trial (2022) showed 20.9% mean weight loss at 72 weeks with 15mg tirzepatide versus 3.1% with placebo — a landmark result that exceeded all prior GLP-1 trial data. SURMOUNT-2 confirmed results in type 2 diabetes populations. Post-market data is accumulating rapidly given the commercial rollout of Zepbound and Mounjaro. Cardiovascular outcomes trial data is pending but expected.
The NEJM 2023 Phase 2 publication showed dose-dependent weight loss from 8.7% (1mg) to 24.2% (12mg) at 48 weeks. The weight loss trajectory had not plateaued — suggesting greater final outcomes with longer treatment. This is the data that has generated intense research and investor interest. Phase 3 is running under the TRIUMPH program; results expected 2025–2026.
Direct head-to-head comparison between tirzepatide and retatrutide doesn't yet exist in a single trial. The 24% vs 21% comparison across separate trials with different patient populations and timepoints should be interpreted cautiously. Phase 3 head-to-head data would be needed for a definitive comparison.
| Priority | Lean Toward | Rationale |
|---|---|---|
| FDA-approved option needed | Tirzepatide | Zepbound approved 2023; retatrutide not yet |
| Maximum weight loss potential | Retatrutide | Phase 2 shows ~3% additional loss vs tirzepatide |
| Liver fat / NASH research | Retatrutide | Glucagon adds hepatic fat oxidation beyond GLP-1/GIP |
| Best safety track record | Tirzepatide | Phase 3 complete + growing post-market data |
| Thermogenesis / energy expenditure | Retatrutide | Glucagon-mediated — unique to retatrutide |
| T2 diabetes management context | Tirzepatide | Mounjaro approved for T2D; retatrutide not |
COA-verified vendor pricing with promo codes from S1 Research and Tegridy Research.
View Pricing → Dosage Calculator